Skip to content
Subscriber Only

Swedish Orphan Said to Be Open to Sale Amid Boom in Drug Deals

Swedish Orphan Biovitrum AB, the maker of treatments for rare diseases, is open to a potential takeover after its stock reached an all-time high amid a boom in pharmaceutical deals, people familiar with the matter said.

Swedish Orphan, whose biggest shareholder is Investor AB, has held on-and-off again talks with potential buyers since last year, said the people, who asked not to be identified because deliberations are private. The Stockholm-based company is currently valued at about 30.8 billion Swedish krona ($3.56 billion).